Analysts expect Endologix, Inc. (NASDAQ:ELGX) to post ($0.22) earnings per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Endologix’s earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.27). Endologix also posted earnings per share of ($0.22) during the same quarter last year. The business is scheduled to announce its next earnings results after the market closes on Wednesday, February 21st.

On average, analysts expect that Endologix will report full-year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.66) to ($0.56). For the next financial year, analysts forecast that the company will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.53) to ($0.46). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Endologix.

A number of research firms recently weighed in on ELGX. Royal Bank of Canada lowered their price objective on shares of Endologix from $5.00 to $4.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 8th. JPMorgan Chase & Co. lowered shares of Endologix from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. ValuEngine lowered shares of Endologix from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Stifel Nicolaus reduced their target price on shares of Endologix from $6.00 to $5.50 and set a “hold” rating on the stock in a report on Wednesday, November 8th. Finally, BidaskClub upgraded shares of Endologix from a “sell” rating to a “hold” rating in a report on Saturday. Three analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. Endologix has an average rating of “Hold” and a consensus target price of $5.41.

A number of institutional investors have recently added to or reduced their stakes in ELGX. Verition Fund Management LLC acquired a new stake in Endologix during the 2nd quarter worth approximately $111,000. Quantitative Systematic Strategies LLC acquired a new stake in Endologix during the 4th quarter worth approximately $139,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Endologix in the 2nd quarter valued at $142,000. Teacher Retirement System of Texas acquired a new stake in shares of Endologix in the 4th quarter valued at $144,000. Finally, Valeo Financial Advisors LLC acquired a new stake in shares of Endologix in the 3rd quarter valued at $163,000.

Endologix (NASDAQ ELGX) traded down $0.17 during trading hours on Wednesday, hitting $4.04. 472,500 shares of the company were exchanged, compared to its average volume of 655,873. The company has a debt-to-equity ratio of 2.61, a current ratio of 2.90 and a quick ratio of 2.11. The stock has a market cap of $351.34, a PE ratio of -4.34 and a beta of 0.42. Endologix has a 1 year low of $3.89 and a 1 year high of $7.66.

ILLEGAL ACTIVITY NOTICE: “Brokerages Expect Endologix, Inc. (ELGX) to Announce -$0.22 EPS” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/14/brokerages-expect-endologix-inc-elgx-to-announce-0-22-eps.html.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Get a free copy of the Zacks research report on Endologix (ELGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.